Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 10/20 | 0.35 |
| ▸ | CDK2 | P24941 | 10/20 | 0.35 |
| ▸ | KDR | P35968 | 9/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206105 | 1.00 | CDK1 (0.35) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL24945000 | 0.92 | CDK1 (0.34) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL30205605 | 0.92 | CDK1 (0.34) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL31195426 | 0.92 | CDK1 (0.34) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL30206330 | 0.90 | SYK (0.30) | — | |
| SCHEMBL30205929 | 0.90 | — | — | |
| SCHEMBL30206107 | 0.86 | CYP1A2 (0.35) | CDK2 | |
| SCHEMBL29173378 | 0.86 | CYP1A2 (0.35) | CDK2 | |
| SCHEMBL29173540 | 0.85 | SYK (0.36) | — | |
| SCHEMBL30206043 | 0.85 | SYK (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | CDK1 229/4885CDK2 177/4885KDR 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.